Hepatocellular Carcinoma: Nursing Implications for Improving Patient Outcomes
Hematology-Oncology
Curriculum:
Hepatocellular Carcinoma: Nursing Implications for Improving Patient Outcomes
Hepatocellular Carcinoma: Nursing Implications for Improving Patient Outcomes
Credits:
1 ANCC Contact Hours
1 ANCC Contact Hours
Launch Date:
May 01, 2014
May 01, 2014
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Nurses and advance practice registered nurses (APRNs) who specialize in oncology, gastroenterology, hematology, pathology, and interventional radiology, and other healthcare professionals involved in the treatment of patients with hepatocellular carcinoma
Relevant Terms:
Diarrhea, Hand-Foot Skin Reaction, HCC, Hepatocellular Carcinoma, Liver Cancer, Oral Therapy Compliance
Carol S. Viele, MS, RN, CNS, OCN®
Carol S. Viele, MS, RN, CNS, OCN®
University of California School of Nursing
San Francisco, CA
Bio
Carol S. Viele is a Clinical Nurse Specialist in hematology-oncology-bone marrow transplant and an Associate Clinical Professor in the Department of Physiological Nursing at the University of California San Francisco Medical Center. She is responsible for the education and teaching of both patients and staff on such topics including specific chemotherapeutic agents, administration techniques, and managing patients' symptoms related to their treatment or disease. Ms. Viele received her Master of Science in Nursing degree from the University of Michigan in Ann Arbor, and has over 30 years of experience in oncology.
Ms. Viele is a member of several professional organizations, including the International Society of Bone Marrow Transplant, American Society of Clinical Oncology, American Nurses Association, and the Oncology Nursing Society. She is a nationally recognized expert in nursing care of cancer patients, with a focus on cutting-edge therapies, including bone marrow transplant.
Ms. Viele is a member of several professional organizations, including the International Society of Bone Marrow Transplant, American Society of Clinical Oncology, American Nurses Association, and the Oncology Nursing Society. She is a nationally recognized expert in nursing care of cancer patients, with a focus on cutting-edge therapies, including bone marrow transplant.
Suzette C. Walker, DNP, RN, FP-BC, AOCNP®
Suzette C. Walker, DNP, RN, FP-BC, AOCNP®
McKenzie Health and Wellness Center
Sandusky, MI
Bio
Dr. Suzette C. Walker is a Nurse Practitioner for the McKenzie Health and Wellness Center in Sandusky, Michigan. She has focused on primary care for 33 years with a specialty in oncology, which enhances the patient-care excellence at McKenzie. Dr. Walker earned her Doctor of Nursing Practice degree from the University of Michigan in Flint. Her DNP was preceded by a Master's Degree from Concordia University in Mequon, Wisconsin; a Bachelor's Degree from University of Michigan in Ann Arbor; and an Associate's Degree from St. Clair County Community College in Port Huron, Michigan. Dr. Walker is widely published in peer-reviewed journals, lectures nationally and internationally, and maintains an active volunteer experience, as well as participating in many different advisory boards.
| 1. | Identify risk factors associated with HCC, including underlying liver disease, to thoroughly assess patients on presentation | 2. | Analyze the mechanism of action of current and emerging targeted agents for the treatment of HCC |
| 3. | Implement treatment and management plans based on current and emerging clinical evidence supporting the use of targeted agents in the treatment of HCC | 4. | Integrate supportive care to avoid early complications that may compromise therapeutic outcomes |
| 5. | Anticipate, monitor, and employ effective strategies to manage side effects associated with targeted therapy for the treatment of HCC | 6. | Employ optimal oral therapy compliance strategies for targeted therapy in the treatment of HCC |
| 7. | Implement multidisciplinary communication strategies regarding treatment options and adherence, as well as management of side effects associated with targeted therapy for HCC |
| 1. | Identify risk factors associated with HCC, including underlying liver disease, to thoroughly assess patients on presentation |
| 2. | Analyze the mechanism of action of current and emerging targeted agents for the treatment of HCC |
| 3. | Implement treatment and management plans based on current and emerging clinical evidence supporting the use of targeted agents in the treatment of HCC |
| 4. | Integrate supportive care to avoid early complications that may compromise therapeutic outcomes |
| 5. | Anticipate, monitor, and employ effective strategies to manage side effects associated with targeted therapy for the treatment of HCC |
| 6. | Employ optimal oral therapy compliance strategies for targeted therapy in the treatment of HCC |
| 7. | Implement multidisciplinary communication strategies regarding treatment options and adherence, as well as management of side effects associated with targeted therapy for HCC |
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
ACCREDITATION STATEMENT
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CREDIT DESIGNATION
This educational activity for 1 contact hour(s) is provided by Postgraduate Institute for Medicine.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1 contact hour.
Designated for 0.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Upon successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.
Upon successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Carol S. Viele, MS, RN, CNS, OCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Novartis Pharmaceuticals Corporation; Speakers' Bureau, Boehringer-Ingelheim, Celgene Corporation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation.
Suzette C. Walker, DNP, FNP-BC, AOCNP®, reported a financial interest/relationship or affiliation in the form of: Consulting Fee, Novartis Pharmaceuticals Corporation; Speakers' Bureau, Bristol-Myers Squibb Company; Speakers' Bureau, Pfizer, Inc.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS, Jocelyn Timko, BS and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Carol S. Viele, MS, RN, CNS, OCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Novartis Pharmaceuticals Corporation; Speakers' Bureau, Boehringer-Ingelheim, Celgene Corporation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation.
Suzette C. Walker, DNP, FNP-BC, AOCNP®, reported a financial interest/relationship or affiliation in the form of: Consulting Fee, Novartis Pharmaceuticals Corporation; Speakers' Bureau, Bristol-Myers Squibb Company; Speakers' Bureau, Pfizer, Inc.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: Linda Gracie-King, MS, Jocelyn Timko, BS and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of the CME activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including, but not limited to, review of all planned content for CME activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's content validation statements, and resolution of any actual or perceived conflicts of interest that exist. We employ three metrics as we review materials:
- Fair balance
- Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
- No single product or service is overrepresented when other equal competing products or services are available for inclusion
- Scientific objectivity of studies mentioned in the materials or used as the basis for content
- Appropriateness of patient care recommendations made to learners
ESTIMATED TIME TO COMPLETE ACTIVITY: 60 minutes
FEE STATEMENT
There is no fee for this educational activity.
CONTACT INFORMATION
To contact PIM, please visit www.pimed.com.
Co-provided by:
This activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals, Inc.
